MRNA241101C46000
- 7.65
- 0.000.00%
Moderna Newsroom
Is Moderna (NASDAQ:MRNA) Stock a Buy at Current Levels?
Halloween Market Falls, Scared of Meta and Microsoft CapEx | Live Stock
Moderna to Present at Upcoming Conferences in November 2024
Market Flips and Falls as Meta and MSTR Fall After Earnings | Wall Street Today
Is Moderna, Inc. (MRNA) The Worst Performing S&P 500 Stock In 2024?
Market Climbs, SMCI Auditors Allege Mischief on Mischief Night | Live Stock
WHO Expands Emergency Use List For Mpox Diagnostics, Adds Cepheid's Xpert Mpox PCR Test And Roche's Cobas MPXV Assay As PCR-Based Gold Standard Options
Novocure Appoints Moderna's Exec Christoph Brackmann as CFO
GSK Dips as Lower Vaccine Sales Weigh on Q3 2024 Results
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider
Nasdaq Hits Record High While Wed Earnings Are Mixed | Wall Street Today
Tuesday Market Falls on Tough Earnings, With AMD and Alphabet Reporting Tonight | Live Stock
Behind the Scenes of Moderna's Latest Options Trends
Express News | BlackRock CEO Larry Fink, Blackstone CEO Stephen Schwarzman, Moderna CEO Stephane Bancel Attend Fii Conference in Riyadh
Slow Day to Start Busy Week | Wall Street Today
Market Climbs as Investors Prepare for Biggest Earnings Week of the Year | Live Stock
Express News | Moderna Shares Are Trading Higher After the Company Announced the Initiation of INTerpath-009 in Combination With KEYTRUDA as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB Non-small Cell Lung Cancer Who Did Not Achieve a...
Evercore Maintains Moderna(MRNA.US) With Hold Rating, Cuts Target Price to $60
Moderna Stock Price Target Slashed. It's About Vaccines. -- Barrons.com
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (MRNA-4157) in Combination With KEYTRUDA (Pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)